Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic

BACKGROUND: CCR5 antagonists have clinically been approved for prevention or treatment of HIV/AIDS. Countries in Sub-Saharan Africa with the highest burden of HIV/AIDS are due to adopt these regimens. However, HIV-1 can also use CXCR4 as a co-receptor. There is hence an urgent need to map out cellul...

Descripción completa

Detalles Bibliográficos
Autores principales: Wambui, Veronica, Kiptoo, Michael, Kinyua, Joyceline, Odera, Irene, Muge, Edward, Muiruri, Peter, Lihana, Raphael, Kinyanjui, Peter, Songok, Elijah M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527298/
https://www.ncbi.nlm.nih.gov/pubmed/22838398
http://dx.doi.org/10.1186/1742-6405-9-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527298/
https://www.ncbi.nlm.nih.gov/pubmed/22838398
http://dx.doi.org/10.1186/1742-6405-9-22

Ejemplares similares